Track CMMB and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Chemomab Therapeutics Ltd DRC
Building C, Tel Aviv-Yafo, Israel, 6158101
IPO
2019
Employees
0
Industry
Biotechnology
Sector
Healthcare
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20231-1
0
Q4 20222-2
0
2-quarter cumulative
3 sells0 buys
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0